← Eichor
Study identifier: NCT06626646 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Vascular Regenerative Cell Exhaustion in Adults with Peripheral Artery Disease (PAD-VRCE)

Condition: Peripheral Vascular Diseases · Cardiovascular Disease · Type 2 Diabetes  ·  Sponsor: Canadian Medical and Surgical Knowledge Translation Research Group

PhaseN/A
Planned participants40
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersYes

About this study

PAD-VRCE is an observational, cross-sectional, two arm study aimed at determining if the presence of peripheral artery disease (PAD) can influence the number of circulating regenerative cells in blood. From peripheral blood samples, circulating progenitor cell content will be assessed via flow cytometry and compared between individuals with PAD and individuals without PAD. Ultimately, this study plans to evaluate the relationship between PAD, vascular regenerative cell exhaustion and overall cardiovascular health.

This description comes directly from the study's public registry record.

Talk to the study team

Jack Casey  ·  604-703-5449  ·  jackcasey21@rcsi.ie

Aishwarya Krishnaraj, BScH  ·  aishy.krishnaraj@mail.utoronto.ca

Always discuss trial participation with your own doctor first.

Locations (2)

North York Diagnostic and Cardiac CentreNorth York, Ontario, CanadaRecruiting
Diagnostic Assessment CentreScarborough Village, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06626646